DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease

Larkin, BP; Glastras, SJ; Chen, H; Pollock, CA; Saad, S

DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease

Larkin, BP Glastras, SJ Chen, H

Pollock, CA Saad, S

Permalink

Publication Type:: Journal Article
Citation:: FASEB Journal, 2018, 32 (10), pp. 5215 - 5226
Issue Date:: 2018-10-01

Closed Access

	Filename	Description	Size
	Larkin_final_accepted.docx	Accepted Manuscript Version	263.85 kB	Microsoft Word XML	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Larkin, BP	en_US
dc.contributor.author	Glastras, SJ	en_US
dc.contributor.author	Chen, H https://orcid.org/0000-0001-6883-3752	en_US
dc.contributor.author	Pollock, CA	en_US
dc.contributor.author	Saad, S https://orcid.org/0000-0001-8067-8046	en_US
dc.date.issued	2018-10-01	en_US
dc.identifier.citation	FASEB Journal, 2018, 32 (10), pp. 5215 - 5226	en_US
dc.identifier.issn	0892-6638	en_US
dc.identifier.uri	http://hdl.handle.net/10453/124053
dc.description.abstract	© 2018 American Society for Biochemistry and Molecular Biology Inc. All rights reserved. Chronic kidney disease (CKD) is a global epidemic, and itsmajor risk factors include obesity and type 2 diabetes. Obesity not only promotes metabolic dysregulation and the development of diabetic kidney disease but alsomay independently lead to CKD by a variety ofmechanisms, including endocrine andmetabolic dysfunction, inflammation, oxidative stress, altered renal hemodynamics, and lipotoxicity. Deleterious renal effects of obesity can also be transmitted from one generation to the next, and it is increasingly recognized that offspring of obese mothers are predisposed to CKD. Epigenetic modifications are changes that regulate gene expression without altering theDNAsequence.Of these,DNAmethylation is the most studied. Epigenetic imprints, particularlyDNA methylation, are laid down during critical periods of fetal development, and they may provide a mechanism by whichmaternal-fetal transmissionof chronic diseaseoccurs.Ourcurrent review explores the evidence for the role of DNAmethylationinthedevelopment ofCKD,diabetickidneydisease,diabetes, andobesity.DNAmethylationhas been implicated in renal fibrosis-the final pathophysiologic pathway in the development of end-stage kidney disease-which supports the notion that demethylating agentsmay play a potential therapeutic role in preventing development and progression of CKD.	en_US
dc.relation.ispartof	FASEB Journal	en_US
dc.relation.isbasedon	10.1096/fj.201800205R	en_US
dc.subject.classification	Biochemistry & Molecular Biology	en_US
dc.subject.mesh	Animals	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Diabetic Nephropathies	en_US
dc.subject.mesh	Kidney Failure, Chronic	en_US
dc.subject.mesh	Diabetes Mellitus, Type 2	en_US
dc.subject.mesh	Obesity	en_US
dc.subject.mesh	Risk Factors	en_US
dc.subject.mesh	DNA Methylation	en_US
dc.title	DNA methylation and the potential role of demethylating agents in prevention of progressive chronic kidney disease	en_US
dc.type	Journal Article
utslib.citation.volume	10	en_US
utslib.citation.volume	32	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
utslib.for	0606 Physiology	en_US
utslib.for	1116 Medical Physiology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	closed_access
pubs.issue	10	en_US
pubs.publication-status	Published	en_US
pubs.volume	32	en_US

Abstract:

© 2018 American Society for Biochemistry and Molecular Biology Inc. All rights reserved. Chronic kidney disease (CKD) is a global epidemic, and itsmajor risk factors include obesity and type 2 diabetes. Obesity not only promotes metabolic dysregulation and the development of diabetic kidney disease but alsomay independently lead to CKD by a variety ofmechanisms, including endocrine andmetabolic dysfunction, inflammation, oxidative stress, altered renal hemodynamics, and lipotoxicity. Deleterious renal effects of obesity can also be transmitted from one generation to the next, and it is increasingly recognized that offspring of obese mothers are predisposed to CKD. Epigenetic modifications are changes that regulate gene expression without altering theDNAsequence.Of these,DNAmethylation is the most studied. Epigenetic imprints, particularlyDNA methylation, are laid down during critical periods of fetal development, and they may provide a mechanism by whichmaternal-fetal transmissionof chronic diseaseoccurs.Ourcurrent review explores the evidence for the role of DNAmethylationinthedevelopment ofCKD,diabetickidneydisease,diabetes, andobesity.DNAmethylationhas been implicated in renal fibrosis-the final pathophysiologic pathway in the development of end-stage kidney disease-which supports the notion that demethylating agentsmay play a potential therapeutic role in preventing development and progression of CKD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/124053